Seeking Alpha

Seeking Alpha Portfolio App for iPad

1,464 people get ZIOP articles and Market Currents by email alert.

Get email alerts on ZIOP »

ZIOP

Ziopharm Oncology Inc

5/22/2013, 2:10 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 7:53 AM Ziopharm (ZIOP) says results from nonclinical and Phase 1 studies show ad-RTS-IL-12 "is clearly a potent immune stimulator with a demonstrated immune mediated effect in melanoma and other cancers." The studies demonstrate that the severe toxicity often associated with the delivery of Il-12 protein can be mediated through a "regulatable gene therapy strategy." A Phase 2 study is underway. The stock (up 1.78% premarket) faces a long road back from a late March collapse triggered by the termination of a Phase 3 trial of palifosfamide. (PR) Comment! [Healthcare]
Tuesday, May 7, 7:30 PM Ziopharm (ZIOP): Q1 EPS of -$0.15 beats by $0.12. Revenue of $200K beats by $40.K. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 9, 9:10 AM Premarket gainers: CLRX +13%. ZIOP +12%. RDN +5%. UNXL +5%.
Losers: OCZ -13%. JCP -7%. Comment! [On the Move]
Tuesday, April 9, 8:31 AM Ziopharm's (ZIOP +8.6%) Ad-RTS-mIL-12 DNA-based therapy has demonstrated anti-tumor effects and tolerability in mice. Ad-RTS-IL-12 is being tested in two Phase 2 studies, one for advanced melanoma and the other for breast cancer. (PR) Comment! [Healthcare, On the Move]
Tuesday, March 26, 12:54 PM Midday top 10 gainers: PTEK +30%. BVX +23%. OPXA +20%. LEDS +20%. IBCP +13%. DXYN +11%. GTAT +11%. APP +11%. HGSH +9%. PGNX +9%.
Midday top 10 losers: ZIOP -62%. FUQI -17%. GMAN -16%. PGTI -14%. STSI -13%. GMXR -11%. STXS -11%. PRTS -10%. REED -10%. CSUN -8%. Comment! [On the Move]
Tuesday, March 26, 11:23 AM Threshold Pharmaceuticals (THLD +1.3%) gains on the back of Ziopharm's (ZIOP -63%) earlier announcement that it's ending Phase 3 trials of palifosfamide after it failed to meet its primary endpoint. An article posted in Seeking Alpha last Friday infers that THLD's competing drug, TH-302, although similar to palifosfamide in molecular structure, is differentiated enough in nature that there is still sufficient reason to believe it could work. Now, with ZIOP's drug out of the running, TH-302's addressable market increases significantly. The company is due to release data from its own Phase III study early next year. 1 Comment [Healthcare, On the Move]
Tuesday, March 26, 9:15 AM Premarket gainers: THLD +8%. CTIC +6%.
Losers: ZIOP -62%. PLCE -6%. PATH -6%. Comment! [On the Move]
Tuesday, March 26, 7:17 AM Ziopharm Oncology (ZIOP) -59% after reporting the failure of palifosfamide in its Phase 3 trial, and saying it is pulling development of the treatment. Kudos to Adam Feurstein's source who was certain enough of the test results to short the stock last week. 3 Comments [Healthcare, On the Move]
Friday, March 22, 9:54 AM Ziopharm Oncology (ZIOP -5.8%) opens down big after Adam Feurstein reports an oft-correct source has shorted the stock ahead of what he/she thinks will be the failure of next week's results of the palifosfamide sarcoma study. Comment! [Healthcare, On the Move]
Friday, March 22, 9:10 AM Premarket gainers: HALO +23%. ANAC +18%. MU +9%. AFFY +8%. NKE +8%.
Losers: TIBX -16%. ABR -6%. ZIOP -5%. Comment! [On the Move]
Monday, March 18, 4:49 PM More on Ziopharm (ZIOP): Q4 comes in-line on revenue but misses on a per shares basis. Operating expenses rose 134% over the prior year, primarily due to an $18.7M non-cash expense associated with the issuance of approximately 3.6M shares of common stock to Intrexon as a milestone payment associated with the dosing of the first patient in its Ad-RTS IL-12 Phase 2 trial. Shares -2% AH. Comment! [Healthcare, Earnings, On the Move]
Monday, March 18, 4:22 PM Ziopharm (ZIOP): Q4 EPS of -$0.37 misses by $0.08. Revenue of $200K beats by $30K. Shares -1.1% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
Wednesday, March 13, 7:18 PM Ziopharm (ZIOP) is getting whipped about in thin after-hours trade this evening following unconfirmed reports that SAC Capital had taken a 5.2% stake in the company. After briefly popping +1.25%, the stock has since fallen back, now trading -0.9%. It's also worth noting that the company also presented at the Barclay's Healthcare Conference a few hours ago as well. (Presentation Webcast) 1 Comment [Healthcare, On the Move]
Monday, March 11, 3:13 PM Ziopharm Oncology (ZIOP +1.8%) trades higher after intitiating Phase 2 clinical studies of Ad-RTS IL-12 in combination with palifosfamide to treat patients with non-resectable recurrent or metastatic breast cancer. Comment! [Healthcare, On the Move]
Wednesday, February 13, 10:07 AM Ziopharm Oncology (ZIOP) is in talks with prospective partners to market palifosfamide, which appears to have performed well in patients with metastatic soft tissue sarcoma in a Phase III trial. Ziopharm may sign a deal before the full study data is known, although the greater likelihood is after its release in March. Ziopharm's shares shot up 18% yesterday on news of the trial, and are now +2.1%. Comment! [Healthcare, On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]